Euclid to establish R&D production base in Jiangsu Medpark

2021年09月03日 11:44:11 | 来源:China daily

字号变大| 字号变小

微信图片_20210901145745.jpg

Euclid Systems Corporation, an orthokeratology producer, signs an agreement with Suzhou New District on Aug 31. [Photo/WeChat account: snd-szgxqfb]

Euclid Systems Corporation, an orthokeratology producer, signed an agreement with Suzhou New District on Aug 31 to establish its research and development production base in Jiangsu Medpark.

With a total investment of 200 million yuan ($30.95 million), the R&D production base will produce products to be sold all over the world. It is its first global production base built outside of its United States headquarters.

The production base is expected to acquire a third class device product registration certificate and achieve mass production by 2026 to meet the requirements of the global market.

Founded in 1994, Euclid Systems Corporation is a global leader in myopia management and advanced orthokeratology, offering vision correction products by advanced inspection, design, and customization systems.

With the establishment of the R&D production base, Euclid Systems Corporation will strive to increase its production capacity in the Asia-Pacific region, as well as promote the development of the Chinese orthokeratology industry, said Cao Qiang, president of Euclid China.

As the only national high-tech district that supports the development of medical equipment, SND is home to medical equipment industrial incubators like Jiangsu Medpark and Inspirationpark, as well as over 400 related companies with a total annual revenue reaching 20 billion yuan.

layer
快乐分享